 |
A. J. Kazimi, is Chief Executive Officer and Chairman of the Board of Directors at CET. Previously, Mr. Kazimi helped guide and build the international biopharmaceutical company Therapeutic Antibodies Inc. As President and Chief Operating Officer, he made key contributions to the company’s growth through its IPO and initial product launches, including oversight of operations in three countries, closing more than $30 million in product agreements, and steering the company through debt and equity financings totaling more than $100 million. At Brown-Forman Corporation, Mr. Kazimi held a series of management positions and was involved in launching several new products. Mr. Kazimi serves on the board of directors for the Nashville Health Care Council, an industry association representing the largest concentration of healthcare companies in the U.S., and previously served on the board of directors for Aegis Toxicology Sciences Corporation, a federally certified forensic toxicology laboratory. Mr. Kazimi’s MBA is from the Owen Graduate School of Management at Vanderbilt University. |
 |
As Director of Corporate Development at CET, Jim Stefansic, Ph.D., MBA, is responsible for sourcing, evaluating and negotiating for new biopharmaceutical product and technology opportunities to support product development, project management and funding initiatives. In addition to a bachelor’s degree in biomedical engineering from Johns Hopkins University, Jim holds a master’s and doctorate in biomedical engineering from Vanderbilt University and a master’s in business administration with a concentration in finance from Belmont University. Jim was a CoFounder & Chief Operating Officer at Pathfinder Therapeutics, where he later served as Chief Technology Officer. He was previously Director of Commercialization at Launch Tennessee, a statewide organization focused on technology development and entrepreneurship. Prior to joining CET, Jim was Co-Founder, President & Chief Executive Officer of Raiven Healthcare/Centerstone Research Institute. Jim currently serves as Adjunct Professor of Business at Belmont University. |
 |
Joseph O. Rolwing, MBA, is Senior Director of the CET Life Sciences Center, having retired in 2010 from the concurrent position President and Executive Director of the Tennessee Biotechnology Association (now known as Life Science Tennessee). Mr. Rolwing’s 38 years of experience in the healthcare industry includes former positions as Vice President and Business Manager for Genetics Associates, Inc., a $3.2 million diagnostic medical lab, and Vice President of Corporate Affairs for Centerstone Community Mental Health Centers, Inc., where he managed care contracts, budgeting, risk management, billing and accounts receivable. Mr. Rolwing also served as Special Projects Director and Finance Director for the Helen Ross McNabb Center in Knoxville, Tennessee. His MBA is from the University of North Carolina-Chapel Hill. |
 |
Andrew Vila, Ph.D., is Senior Formulation Scientist at Cumberland Pharmaceuticals Inc. and manages Cumberland’s formulation laboratories. Dr. Vila provides formulation and analytical support for Cumberland Pharmaceuticals’ marketed and pipeline drug products and early-stage drug candidates in CET’s project portfolio. Previously, Dr. Vila was appointed Post-doctoral Fellow and then Research Instructor for the Vanderbilt Institute of Chemical Biology. Dr. Vila’s original research is published in peer-reviewed biochemical journals. |